Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corning Inc
LSE:0R2X
|
US |
|
HanmiGlobal Co Ltd
KRX:053690
|
KR |
|
Nexgen Energy Ltd
TSX:NXE
|
CA |
|
A
|
Alphageo (India) Ltd
NSE:ALPHAGEO
|
IN |
|
U
|
Unique Engineering and Construction PCL
SET:UNIQ
|
TH |
|
Inspira Technologies Oxy BHN Ltd
NASDAQ:IINN
|
IL |
|
Imax Corp
NYSE:IMAX
|
CA |
|
T
|
Tesla Inc
BMV:TSLA
|
US |
|
B
|
Bestechnic Shanghai Co Ltd
SSE:688608
|
CN |
Paradigm Biopharmaceuticals Ltd
Research & Development
Paradigm Biopharmaceuticals Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Research & Development
-AU$32.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Research & Development
-AU$7.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Research & Development?
Research & Development
-32.8m
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Research & Development amounts to -32.8m AUD.
What is Paradigm Biopharmaceuticals Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
Over the last year, the Research & Development growth was -106%. The average annual Research & Development growth rates for Paradigm Biopharmaceuticals Ltd have been 9% over the past three years , -5% over the past five years .
